Abstract
The results of KEYNOTE-164 and 158 show the efficacy of Pembrolizumab for MSI-High solid tumors. However, the frequency of MSI-High is low, so real-world data is still inadequate. Therefore, we investigated the frequency of MSI-High solid tumors in our hospital and examined the efficacy and safety of Pembrolizumab for unresectable cases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
